1. Home
  2. PRLD vs TYGO Comparison

PRLD vs TYGO Comparison

Compare PRLD & TYGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • TYGO
  • Stock Information
  • Founded
  • PRLD 2016
  • TYGO 2007
  • Country
  • PRLD United States
  • TYGO United States
  • Employees
  • PRLD N/A
  • TYGO N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • TYGO Semiconductors
  • Sector
  • PRLD Health Care
  • TYGO Technology
  • Exchange
  • PRLD Nasdaq
  • TYGO Nasdaq
  • Market Cap
  • PRLD 73.7M
  • TYGO 63.2M
  • IPO Year
  • PRLD 2020
  • TYGO N/A
  • Fundamental
  • Price
  • PRLD $0.68
  • TYGO $0.73
  • Analyst Decision
  • PRLD Strong Buy
  • TYGO Buy
  • Analyst Count
  • PRLD 2
  • TYGO 3
  • Target Price
  • PRLD $4.50
  • TYGO $3.00
  • AVG Volume (30 Days)
  • PRLD 272.4K
  • TYGO 22.4K
  • Earning Date
  • PRLD 05-06-2025
  • TYGO 05-13-2025
  • Dividend Yield
  • PRLD N/A
  • TYGO N/A
  • EPS Growth
  • PRLD N/A
  • TYGO N/A
  • EPS
  • PRLD N/A
  • TYGO N/A
  • Revenue
  • PRLD $7,000,000.00
  • TYGO $54,014,000.00
  • Revenue This Year
  • PRLD N/A
  • TYGO $61.65
  • Revenue Next Year
  • PRLD N/A
  • TYGO $28.03
  • P/E Ratio
  • PRLD N/A
  • TYGO N/A
  • Revenue Growth
  • PRLD N/A
  • TYGO N/A
  • 52 Week Low
  • PRLD $0.63
  • TYGO $0.60
  • 52 Week High
  • PRLD $6.80
  • TYGO $1.85
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 41.40
  • TYGO 30.82
  • Support Level
  • PRLD $0.71
  • TYGO $0.85
  • Resistance Level
  • PRLD $0.76
  • TYGO $0.95
  • Average True Range (ATR)
  • PRLD 0.07
  • TYGO 0.10
  • MACD
  • PRLD 0.01
  • TYGO -0.02
  • Stochastic Oscillator
  • PRLD 18.75
  • TYGO 33.30

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About TYGO Tigo Energy Inc.

Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.

Share on Social Networks: